Graftys completed a €4.1MM (~US $4.6MM) funding round. Graftys markets Graftys® QuickSet calcium phosphate cement and Graftys® HBS injectable calcium phosphate bone graft substitute through distribution partnerships in over 25 countries.
Proceeds will support global expansion by building new commercial/business development, clinical/regulatory and production capabilities in Belgium; reinforcing cement bulk production and creating a design unit in France; developing current markets such as Europe and the U.S.; and entering markets where Graftys has no current presence, such as Asia. Further, the company intends to develop new versions of existing products and new products with enhanced regenerative properties.
Source: Graftys
Graftys completed a €4.1MM (~US $4.6MM) funding round. Graftys markets Graftys® QuickSet calcium phosphate cement and Graftys® HBS injectable calcium phosphate bone graft substitute through distribution partnerships in over 25 countries.
Proceeds will support global expansion by building new commercial/business development, clinical/regulatory...
Graftys completed a €4.1MM (~US $4.6MM) funding round. Graftys markets Graftys® QuickSet calcium phosphate cement and Graftys® HBS injectable calcium phosphate bone graft substitute through distribution partnerships in over 25 countries.
Proceeds will support global expansion by building new commercial/business development, clinical/regulatory and production capabilities in Belgium; reinforcing cement bulk production and creating a design unit in France; developing current markets such as Europe and the U.S.; and entering markets where Graftys has no current presence, such as Asia. Further, the company intends to develop new versions of existing products and new products with enhanced regenerative properties.
Source: Graftys
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
